| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 137 | 2023 | 2303 | 14.340 |
Why?
|
| Anti-HIV Agents | 42 | 2021 | 420 | 5.690 |
Why?
|
| Monocytes | 27 | 2023 | 257 | 5.180 |
Why?
|
| HIV-1 | 45 | 2022 | 706 | 4.340 |
Why?
|
| Antiretroviral Therapy, Highly Active | 34 | 2023 | 221 | 3.760 |
Why?
|
| Leukocytes, Mononuclear | 17 | 2024 | 234 | 2.730 |
Why?
|
| Cognition Disorders | 17 | 2022 | 233 | 2.710 |
Why?
|
| AIDS Dementia Complex | 19 | 2021 | 102 | 2.480 |
Why?
|
| Middle Aged | 99 | 2023 | 10129 | 2.390 |
Why?
|
| Humans | 175 | 2024 | 37093 | 2.160 |
Why?
|
| Insulin Resistance | 10 | 2020 | 184 | 2.140 |
Why?
|
| Male | 129 | 2023 | 20025 | 2.100 |
Why?
|
| Atherosclerosis | 9 | 2020 | 134 | 1.980 |
Why?
|
| Female | 119 | 2021 | 20969 | 1.910 |
Why?
|
| Anti-Retroviral Agents | 13 | 2022 | 147 | 1.840 |
Why?
|
| Viral Load | 21 | 2021 | 312 | 1.780 |
Why?
|
| Benzoxazines | 12 | 2022 | 46 | 1.690 |
Why?
|
| CD4-Positive T-Lymphocytes | 9 | 2021 | 259 | 1.570 |
Why?
|
| DNA, Viral | 14 | 2016 | 304 | 1.570 |
Why?
|
| Adult | 91 | 2023 | 11712 | 1.530 |
Why?
|
| Mitochondria | 8 | 2020 | 487 | 1.520 |
Why?
|
| Neuropsychological Tests | 12 | 2018 | 259 | 1.470 |
Why?
|
| Aging | 12 | 2023 | 664 | 1.460 |
Why?
|
| Cross-Sectional Studies | 36 | 2023 | 2721 | 1.420 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 7 | 2019 | 31 | 1.400 |
Why?
|
| Cognition | 8 | 2018 | 398 | 1.380 |
Why?
|
| CD4 Lymphocyte Count | 23 | 2021 | 189 | 1.360 |
Why?
|
| Adipose Tissue | 4 | 2016 | 177 | 1.320 |
Why?
|
| Carotid Artery Diseases | 2 | 2020 | 22 | 1.280 |
Why?
|
| Peripheral Nervous System Diseases | 4 | 2015 | 28 | 1.270 |
Why?
|
| DNA, Mitochondrial | 6 | 2019 | 175 | 1.230 |
Why?
|
| Vitamin D | 3 | 2016 | 196 | 1.190 |
Why?
|
| Hawaii | 23 | 2022 | 1929 | 1.180 |
Why?
|
| RNA, Viral | 18 | 2020 | 301 | 1.170 |
Why?
|
| Inflammation | 14 | 2023 | 618 | 1.170 |
Why?
|
| Cohort Studies | 29 | 2022 | 1492 | 1.160 |
Why?
|
| Cardiovascular Diseases | 7 | 2022 | 664 | 1.140 |
Why?
|
| HIV Seropositivity | 7 | 2014 | 190 | 1.100 |
Why?
|
| Metformin | 3 | 2023 | 65 | 1.050 |
Why?
|
| Coronary Artery Disease | 3 | 2019 | 142 | 1.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 8 | 2014 | 215 | 1.020 |
Why?
|
| Risk Factors | 20 | 2023 | 3562 | 1.010 |
Why?
|
| Oxidative Phosphorylation | 3 | 2020 | 53 | 0.970 |
Why?
|
| Receptors, Immunologic | 3 | 2020 | 61 | 0.970 |
Why?
|
| HIV | 9 | 2021 | 98 | 0.970 |
Why?
|
| Granulocytes | 2 | 2023 | 29 | 0.960 |
Why?
|
| Latent Tuberculosis | 1 | 2023 | 2 | 0.940 |
Why?
|
| Calcium | 4 | 2020 | 480 | 0.930 |
Why?
|
| Receptors, CCR5 | 4 | 2018 | 61 | 0.910 |
Why?
|
| Guideline Adherence | 1 | 2023 | 84 | 0.900 |
Why?
|
| Polyneuropathies | 2 | 2013 | 10 | 0.880 |
Why?
|
| Tuberculosis | 1 | 2023 | 63 | 0.870 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 485 | 0.860 |
Why?
|
| Viremia | 5 | 2021 | 42 | 0.850 |
Why?
|
| Niacin | 3 | 2013 | 22 | 0.830 |
Why?
|
| Receptors, CCR2 | 4 | 2018 | 26 | 0.830 |
Why?
|
| Coronary Vessels | 3 | 2020 | 85 | 0.830 |
Why?
|
| Central Nervous System Diseases | 2 | 2019 | 29 | 0.820 |
Why?
|
| Bone Diseases | 2 | 2020 | 18 | 0.810 |
Why?
|
| Cerebrovascular Disorders | 3 | 2012 | 37 | 0.810 |
Why?
|
| Cytokines | 7 | 2023 | 602 | 0.810 |
Why?
|
| Hepatitis C | 2 | 2022 | 125 | 0.790 |
Why?
|
| CD4-CD8 Ratio | 3 | 2020 | 30 | 0.780 |
Why?
|
| Hospitalization | 2 | 2014 | 388 | 0.780 |
Why?
|
| Gonorrhea | 1 | 2021 | 24 | 0.770 |
Why?
|
| Skin | 3 | 2015 | 174 | 0.760 |
Why?
|
| Albuminuria | 3 | 2016 | 76 | 0.760 |
Why?
|
| Carotid Stenosis | 1 | 2020 | 13 | 0.750 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 169 | 0.750 |
Why?
|
| Hippocampus | 2 | 2016 | 561 | 0.740 |
Why?
|
| T-Lymphocytes | 3 | 2020 | 357 | 0.730 |
Why?
|
| Cyclohexanes | 2 | 2023 | 30 | 0.720 |
Why?
|
| Macrophages | 3 | 2014 | 439 | 0.720 |
Why?
|
| Reverse Transcriptase Inhibitors | 10 | 2019 | 57 | 0.700 |
Why?
|
| Body Fat Distribution | 3 | 2016 | 24 | 0.700 |
Why?
|
| Atrophy | 3 | 2016 | 42 | 0.690 |
Why?
|
| Cyclopropanes | 12 | 2022 | 40 | 0.690 |
Why?
|
| Carotid Arteries | 3 | 2022 | 28 | 0.690 |
Why?
|
| Alkynes | 12 | 2022 | 50 | 0.690 |
Why?
|
| Nerve Fibers | 3 | 2014 | 34 | 0.680 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2021 | 164 | 0.680 |
Why?
|
| Triazoles | 2 | 2023 | 86 | 0.680 |
Why?
|
| Lipoproteins, LDL | 2 | 2020 | 62 | 0.670 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2023 | 159 | 0.670 |
Why?
|
| Zidovudine | 8 | 2015 | 34 | 0.620 |
Why?
|
| Lymphocyte Activation | 5 | 2020 | 236 | 0.620 |
Why?
|
| Brain | 7 | 2022 | 1346 | 0.610 |
Why?
|
| Aged | 23 | 2023 | 6741 | 0.580 |
Why?
|
| Interleukin-6 | 4 | 2020 | 153 | 0.570 |
Why?
|
| Autonomic Nervous System Diseases | 2 | 2013 | 12 | 0.560 |
Why?
|
| Chemokine CCL2 | 2 | 2016 | 85 | 0.550 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2015 | 13 | 0.550 |
Why?
|
| Bilirubin | 1 | 2016 | 17 | 0.540 |
Why?
|
| Deoxyguanosine | 1 | 2016 | 35 | 0.540 |
Why?
|
| Calcinosis | 2 | 2016 | 59 | 0.530 |
Why?
|
| Oxidative Stress | 4 | 2019 | 938 | 0.520 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2016 | 93 | 0.520 |
Why?
|
| Pilot Projects | 7 | 2020 | 661 | 0.510 |
Why?
|
| Retrospective Studies | 13 | 2023 | 2026 | 0.510 |
Why?
|
| Sensory Receptor Cells | 1 | 2015 | 32 | 0.500 |
Why?
|
| Thailand | 10 | 2015 | 48 | 0.500 |
Why?
|
| C-Reactive Protein | 3 | 2015 | 149 | 0.490 |
Why?
|
| Plasma | 2 | 2017 | 31 | 0.490 |
Why?
|
| Lipoproteins, HDL | 1 | 2014 | 46 | 0.490 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2020 | 356 | 0.490 |
Why?
|
| Vasodilation | 2 | 2015 | 65 | 0.480 |
Why?
|
| Dementia | 2 | 2014 | 131 | 0.470 |
Why?
|
| Mitochondrial Proteins | 2 | 2019 | 107 | 0.470 |
Why?
|
| Reflex | 1 | 2013 | 34 | 0.460 |
Why?
|
| Cholesterol | 1 | 2014 | 205 | 0.450 |
Why?
|
| Social Work | 1 | 2013 | 49 | 0.450 |
Why?
|
| Drug Resistance, Viral | 7 | 2017 | 63 | 0.450 |
Why?
|
| Receptors, IgG | 5 | 2022 | 50 | 0.450 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2017 | 41 | 0.430 |
Why?
|
| Body Mass Index | 3 | 2013 | 854 | 0.430 |
Why?
|
| Glomerular Filtration Rate | 3 | 2023 | 139 | 0.430 |
Why?
|
| Withholding Treatment | 3 | 2012 | 30 | 0.430 |
Why?
|
| Age Factors | 7 | 2018 | 1033 | 0.420 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2021 | 481 | 0.420 |
Why?
|
| Caudate Nucleus | 1 | 2012 | 20 | 0.420 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2012 | 35 | 0.410 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 105 | 0.400 |
Why?
|
| Blood Glucose | 5 | 2020 | 353 | 0.400 |
Why?
|
| Vascular Diseases | 1 | 2011 | 30 | 0.400 |
Why?
|
| Endothelial Cells | 2 | 2018 | 308 | 0.400 |
Why?
|
| Antigens, CD | 4 | 2021 | 121 | 0.390 |
Why?
|
| Longitudinal Studies | 8 | 2019 | 885 | 0.390 |
Why?
|
| Polymerase Chain Reaction | 5 | 2016 | 448 | 0.380 |
Why?
|
| Subcutaneous Fat | 2 | 2019 | 15 | 0.370 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2010 | 13 | 0.370 |
Why?
|
| Hypertriglyceridemia | 1 | 2010 | 14 | 0.370 |
Why?
|
| Hepacivirus | 2 | 2022 | 62 | 0.360 |
Why?
|
| Vietnam | 6 | 2022 | 50 | 0.360 |
Why?
|
| Cerebral Cortex | 4 | 2017 | 290 | 0.360 |
Why?
|
| Models, Immunological | 1 | 2010 | 21 | 0.360 |
Why?
|
| Cholesterol, HDL | 1 | 2010 | 97 | 0.360 |
Why?
|
| Lipoproteins | 3 | 2014 | 64 | 0.350 |
Why?
|
| Healthcare Disparities | 1 | 2014 | 494 | 0.350 |
Why?
|
| HLA-DR Antigens | 2 | 2022 | 21 | 0.340 |
Why?
|
| Lipodystrophy | 3 | 2006 | 8 | 0.340 |
Why?
|
| Mutation | 3 | 2021 | 1095 | 0.340 |
Why?
|
| Mycoses | 3 | 2017 | 30 | 0.340 |
Why?
|
| Motor Skills Disorders | 1 | 2008 | 3 | 0.330 |
Why?
|
| Leukocyte Count | 3 | 2019 | 77 | 0.330 |
Why?
|
| Apolipoprotein E4 | 1 | 2008 | 47 | 0.320 |
Why?
|
| Needs Assessment | 1 | 2009 | 170 | 0.310 |
Why?
|
| Prospective Studies | 12 | 2019 | 1378 | 0.300 |
Why?
|
| HIV Seronegativity | 2 | 2005 | 39 | 0.300 |
Why?
|
| Galectins | 2 | 2018 | 28 | 0.300 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 400 | 0.300 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 2379 | 0.300 |
Why?
|
| DNA Methylation | 3 | 2023 | 325 | 0.290 |
Why?
|
| Penicillium | 3 | 2011 | 5 | 0.290 |
Why?
|
| Central Nervous System | 2 | 2018 | 135 | 0.280 |
Why?
|
| Oxygen Consumption | 3 | 2017 | 103 | 0.280 |
Why?
|
| Phenotype | 4 | 2022 | 689 | 0.280 |
Why?
|
| Prefrontal Cortex | 2 | 2018 | 137 | 0.280 |
Why?
|
| Heart Rate | 6 | 2017 | 253 | 0.270 |
Why?
|
| Population | 1 | 2005 | 10 | 0.270 |
Why?
|
| Mitochondrial Diseases | 1 | 2005 | 16 | 0.260 |
Why?
|
| Stavudine | 3 | 2015 | 13 | 0.260 |
Why?
|
| Proteins | 1 | 2008 | 369 | 0.260 |
Why?
|
| HIV Wasting Syndrome | 1 | 2005 | 8 | 0.260 |
Why?
|
| Immunophenotyping | 2 | 2016 | 57 | 0.260 |
Why?
|
| Physical Fitness | 2 | 2017 | 90 | 0.260 |
Why?
|
| Prevalence | 8 | 2019 | 1455 | 0.250 |
Why?
|
| Neopterin | 2 | 2022 | 13 | 0.250 |
Why?
|
| Antibodies, Neutralizing | 3 | 2022 | 109 | 0.250 |
Why?
|
| Adolescent | 9 | 2019 | 5363 | 0.240 |
Why?
|
| HIV Protease Inhibitors | 3 | 2015 | 23 | 0.240 |
Why?
|
| Killer Cells, Natural | 2 | 2022 | 92 | 0.240 |
Why?
|
| Young Adult | 10 | 2021 | 4268 | 0.240 |
Why?
|
| Antifungal Agents | 3 | 2017 | 148 | 0.240 |
Why?
|
| Blood Platelets | 2 | 2023 | 77 | 0.230 |
Why?
|
| Myeloid Cells | 2 | 2024 | 29 | 0.230 |
Why?
|
| Pulmonary Fibrosis | 1 | 2024 | 31 | 0.230 |
Why?
|
| Galectin 3 | 1 | 2023 | 26 | 0.230 |
Why?
|
| Weight Gain | 1 | 2004 | 136 | 0.230 |
Why?
|
| Lamivudine | 6 | 2012 | 20 | 0.230 |
Why?
|
| Brachial Artery | 2 | 2015 | 28 | 0.220 |
Why?
|
| Dideoxynucleosides | 5 | 2010 | 11 | 0.220 |
Why?
|
| Adiposity | 1 | 2004 | 154 | 0.220 |
Why?
|
| Treatment Outcome | 10 | 2015 | 1369 | 0.220 |
Why?
|
| Fetal Blood | 1 | 2003 | 50 | 0.220 |
Why?
|
| Neutrophils | 1 | 2023 | 131 | 0.210 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2003 | 72 | 0.210 |
Why?
|
| Placenta | 1 | 2003 | 97 | 0.210 |
Why?
|
| Flow Cytometry | 5 | 2016 | 399 | 0.210 |
Why?
|
| Delayed-Action Preparations | 3 | 2013 | 60 | 0.210 |
Why?
|
| Phylogeny | 2 | 2022 | 644 | 0.210 |
Why?
|
| Histones | 1 | 2023 | 190 | 0.200 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2003 | 103 | 0.200 |
Why?
|
| Electrocardiography | 3 | 2017 | 156 | 0.190 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 610 | 0.190 |
Why?
|
| Case-Control Studies | 7 | 2019 | 1130 | 0.190 |
Why?
|
| Cystatin C | 1 | 2020 | 24 | 0.190 |
Why?
|
| Host-Pathogen Interactions | 2 | 2020 | 186 | 0.190 |
Why?
|
| Erythrocyte Indices | 2 | 2018 | 13 | 0.180 |
Why?
|
| Genome, Viral | 1 | 2021 | 109 | 0.180 |
Why?
|
| Fibrosis | 2 | 2022 | 159 | 0.180 |
Why?
|
| Autoantibodies | 1 | 2021 | 103 | 0.180 |
Why?
|
| Interferon Regulatory Factors | 1 | 2019 | 17 | 0.180 |
Why?
|
| Disease Progression | 6 | 2024 | 601 | 0.180 |
Why?
|
| Itraconazole | 2 | 2017 | 12 | 0.170 |
Why?
|
| Uganda | 1 | 2019 | 22 | 0.170 |
Why?
|
| Research | 1 | 2021 | 163 | 0.170 |
Why?
|
| Genotype | 3 | 2019 | 730 | 0.170 |
Why?
|
| Autonomic Nervous System | 2 | 2012 | 33 | 0.170 |
Why?
|
| Membrane Glycoproteins | 2 | 2022 | 211 | 0.170 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2014 | 289 | 0.170 |
Why?
|
| Adipocytes | 1 | 2019 | 58 | 0.170 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2018 | 21 | 0.170 |
Why?
|
| Genetic Markers | 1 | 2019 | 142 | 0.160 |
Why?
|
| Gene Expression | 2 | 2014 | 674 | 0.160 |
Why?
|
| E-Selectin | 1 | 2018 | 21 | 0.160 |
Why?
|
| Hepatitis C, Chronic | 1 | 2019 | 39 | 0.160 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 196 | 0.160 |
Why?
|
| Macrophage Activation | 1 | 2018 | 56 | 0.160 |
Why?
|
| Interleukin-1beta | 2 | 2020 | 70 | 0.160 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 144 | 0.160 |
Why?
|
| Erythrocytes | 1 | 2018 | 111 | 0.160 |
Why?
|
| Research Design | 2 | 2013 | 313 | 0.150 |
Why?
|
| Imidazoles | 1 | 2018 | 126 | 0.150 |
Why?
|
| Neural Pathways | 1 | 2018 | 124 | 0.150 |
Why?
|
| Talaromyces | 1 | 2017 | 1 | 0.150 |
Why?
|
| Incidence | 5 | 2012 | 922 | 0.150 |
Why?
|
| Deoxycholic Acid | 1 | 2017 | 10 | 0.150 |
Why?
|
| Amphotericin B | 1 | 2017 | 24 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2016 | 214 | 0.150 |
Why?
|
| Prognosis | 2 | 2019 | 739 | 0.150 |
Why?
|
| Cell Respiration | 1 | 2017 | 35 | 0.150 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2017 | 23 | 0.150 |
Why?
|
| Double-Blind Method | 6 | 2007 | 286 | 0.150 |
Why?
|
| Statistics, Nonparametric | 3 | 2012 | 108 | 0.150 |
Why?
|
| Sympathetic Nervous System | 1 | 2017 | 74 | 0.150 |
Why?
|
| Nerve Net | 1 | 2017 | 76 | 0.140 |
Why?
|
| Carotid Artery, Common | 1 | 2016 | 9 | 0.140 |
Why?
|
| HIV Reverse Transcriptase | 3 | 2017 | 33 | 0.140 |
Why?
|
| Hypertension | 1 | 2003 | 796 | 0.140 |
Why?
|
| Virus Activation | 1 | 2016 | 35 | 0.140 |
Why?
|
| Virus Latency | 1 | 2016 | 42 | 0.140 |
Why?
|
| Antiviral Agents | 2 | 2010 | 157 | 0.140 |
Why?
|
| Lactic Acid | 2 | 2007 | 95 | 0.140 |
Why?
|
| Reference Values | 2 | 2013 | 212 | 0.140 |
Why?
|
| Proviruses | 2 | 2007 | 29 | 0.140 |
Why?
|
| Energy Metabolism | 1 | 2017 | 168 | 0.140 |
Why?
|
| Absorptiometry, Photon | 1 | 2016 | 75 | 0.140 |
Why?
|
| Body Composition | 2 | 2007 | 162 | 0.130 |
Why?
|
| Memory | 3 | 2012 | 170 | 0.130 |
Why?
|
| Diagnostic Equipment | 1 | 2015 | 3 | 0.130 |
Why?
|
| Chronic Disease | 2 | 2016 | 484 | 0.130 |
Why?
|
| Serum Amyloid P-Component | 1 | 2015 | 20 | 0.130 |
Why?
|
| Minority Groups | 1 | 2021 | 596 | 0.130 |
Why?
|
| Lymphocyte Count | 2 | 2014 | 46 | 0.130 |
Why?
|
| Seasons | 2 | 2013 | 112 | 0.130 |
Why?
|
| Amblyopia | 1 | 2015 | 13 | 0.130 |
Why?
|
| Homosexuality, Male | 1 | 2021 | 458 | 0.130 |
Why?
|
| Blood Pressure | 2 | 2013 | 646 | 0.130 |
Why?
|
| Leg | 1 | 2015 | 19 | 0.130 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2014 | 88 | 0.130 |
Why?
|
| Vision Screening | 1 | 2015 | 21 | 0.130 |
Why?
|
| Acute-Phase Proteins | 1 | 2014 | 14 | 0.130 |
Why?
|
| HIV Antibodies | 2 | 2012 | 30 | 0.120 |
Why?
|
| Epidermis | 1 | 2014 | 24 | 0.120 |
Why?
|
| Psychomotor Performance | 2 | 2012 | 136 | 0.120 |
Why?
|
| HIV-2 | 1 | 2014 | 9 | 0.120 |
Why?
|
| Nevirapine | 2 | 2012 | 7 | 0.120 |
Why?
|
| Disease Management | 1 | 2014 | 61 | 0.120 |
Why?
|
| Particle Size | 1 | 2014 | 215 | 0.120 |
Why?
|
| Japan | 1 | 2014 | 305 | 0.120 |
Why?
|
| Age Distribution | 2 | 2012 | 225 | 0.120 |
Why?
|
| Educational Status | 2 | 2012 | 313 | 0.120 |
Why?
|
| Ferrosoferric Oxide | 1 | 2013 | 11 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 71 | 0.120 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2013 | 28 | 0.120 |
Why?
|
| Depression | 2 | 2018 | 712 | 0.110 |
Why?
|
| Oxygen | 1 | 2014 | 207 | 0.110 |
Why?
|
| DNA Damage | 1 | 2016 | 352 | 0.110 |
Why?
|
| Trail Making Test | 1 | 2013 | 3 | 0.110 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 461 | 0.110 |
Why?
|
| Cerebellum | 1 | 2013 | 73 | 0.110 |
Why?
|
| Receptors, Chemokine | 1 | 2013 | 70 | 0.110 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2012 | 18 | 0.100 |
Why?
|
| Adenine | 2 | 2012 | 44 | 0.100 |
Why?
|
| Phosphorylation | 1 | 2014 | 928 | 0.100 |
Why?
|
| Exercise | 1 | 2017 | 613 | 0.100 |
Why?
|
| Arteries | 1 | 2011 | 65 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2011 | 61 | 0.100 |
Why?
|
| Psychological Tests | 1 | 2011 | 53 | 0.100 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2010 | 1 | 0.100 |
Why?
|
| Anus Diseases | 1 | 2011 | 17 | 0.100 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 11 | 0.100 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 13 | 0.100 |
Why?
|
| Recurrence | 1 | 2011 | 131 | 0.090 |
Why?
|
| Anal Canal | 1 | 2011 | 30 | 0.090 |
Why?
|
| Virus Replication | 2 | 2011 | 278 | 0.090 |
Why?
|
| Antigen Presentation | 1 | 2010 | 54 | 0.090 |
Why?
|
| Liver Function Tests | 1 | 2010 | 18 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2010 | 643 | 0.090 |
Why?
|
| Time Factors | 4 | 2017 | 1742 | 0.090 |
Why?
|
| Bacteriocins | 1 | 2009 | 7 | 0.090 |
Why?
|
| Cryptococcus neoformans | 1 | 2010 | 56 | 0.090 |
Why?
|
| Complement System Proteins | 1 | 2009 | 21 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2010 | 83 | 0.090 |
Why?
|
| Canarypox virus | 1 | 2009 | 3 | 0.090 |
Why?
|
| Leprosy | 1 | 2009 | 2 | 0.090 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2009 | 2 | 0.090 |
Why?
|
| Vaccinia virus | 1 | 2009 | 10 | 0.080 |
Why?
|
| Neurologic Examination | 1 | 2008 | 30 | 0.080 |
Why?
|
| Health Care Surveys | 1 | 2009 | 136 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2010 | 268 | 0.080 |
Why?
|
| Lipids | 2 | 2007 | 235 | 0.080 |
Why?
|
| Glucose | 1 | 2010 | 230 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2008 | 117 | 0.080 |
Why?
|
| Immunoassay | 1 | 2008 | 61 | 0.080 |
Why?
|
| Oxazines | 2 | 2006 | 26 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2010 | 179 | 0.080 |
Why?
|
| Interviews as Topic | 1 | 2009 | 381 | 0.080 |
Why?
|
| Survival Rate | 1 | 2008 | 311 | 0.080 |
Why?
|
| Health Services Research | 1 | 2008 | 148 | 0.080 |
Why?
|
| Pyrimidinones | 1 | 2007 | 9 | 0.080 |
Why?
|
| Ritonavir | 1 | 2007 | 14 | 0.080 |
Why?
|
| Treatment Failure | 3 | 2015 | 64 | 0.070 |
Why?
|
| Interleukin-8 | 2 | 2020 | 60 | 0.070 |
Why?
|
| Sex Factors | 1 | 2010 | 898 | 0.070 |
Why?
|
| Anemia, Macrocytic | 1 | 2007 | 2 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 146 | 0.070 |
Why?
|
| Mental Status Schedule | 1 | 2006 | 14 | 0.070 |
Why?
|
| Abdominal Fat | 1 | 2006 | 21 | 0.070 |
Why?
|
| Acidosis, Lactic | 1 | 2006 | 4 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2022 | 290 | 0.070 |
Why?
|
| Logistic Models | 3 | 2019 | 923 | 0.070 |
Why?
|
| Body Weight | 2 | 2006 | 434 | 0.070 |
Why?
|
| Regression Analysis | 3 | 2014 | 455 | 0.070 |
Why?
|
| Papillomavirus Infections | 1 | 2011 | 336 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 2 | 2018 | 75 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 448 | 0.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2006 | 12 | 0.070 |
Why?
|
| Infant | 3 | 2019 | 1046 | 0.070 |
Why?
|
| Dyslipidemias | 1 | 2006 | 43 | 0.070 |
Why?
|
| Indians, North American | 1 | 2008 | 159 | 0.070 |
Why?
|
| Testosterone | 1 | 2006 | 193 | 0.070 |
Why?
|
| Glucose Intolerance | 1 | 2005 | 42 | 0.060 |
Why?
|
| Comorbidity | 3 | 2016 | 623 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2019 | 1418 | 0.060 |
Why?
|
| Acetylcarnitine | 1 | 2004 | 8 | 0.060 |
Why?
|
| Immunity, Innate | 2 | 2019 | 149 | 0.060 |
Why?
|
| Drug Therapy, Combination | 4 | 2007 | 227 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2005 | 90 | 0.060 |
Why?
|
| Computer Systems | 1 | 2004 | 19 | 0.060 |
Why?
|
| Hemostasis | 1 | 2023 | 6 | 0.060 |
Why?
|
| Nucleosides | 1 | 2004 | 30 | 0.060 |
Why?
|
| Base Sequence | 2 | 2003 | 997 | 0.060 |
Why?
|
| Bystander Effect | 1 | 2023 | 11 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2015 | 974 | 0.060 |
Why?
|
| Leukocytes | 1 | 2023 | 72 | 0.060 |
Why?
|
| Prednisolone | 1 | 2003 | 13 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 106 | 0.060 |
Why?
|
| United States | 1 | 2013 | 4223 | 0.060 |
Why?
|
| ROC Curve | 2 | 2013 | 138 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2024 | 161 | 0.050 |
Why?
|
| Hepatitis C Antibodies | 1 | 2002 | 10 | 0.050 |
Why?
|
| Pregnancy | 2 | 2011 | 1549 | 0.050 |
Why?
|
| Epidemiologic Studies | 1 | 2002 | 31 | 0.050 |
Why?
|
| Receptors, CCR7 | 1 | 2022 | 11 | 0.050 |
Why?
|
| Chemokines | 1 | 2023 | 97 | 0.050 |
Why?
|
| DNA Primers | 1 | 2003 | 286 | 0.050 |
Why?
|
| Torque teno virus | 1 | 2002 | 10 | 0.050 |
Why?
|
| Epitopes | 1 | 2022 | 148 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2002 | 15 | 0.050 |
Why?
|
| Haplotypes | 2 | 2014 | 182 | 0.050 |
Why?
|
| DNA Virus Infections | 1 | 2002 | 16 | 0.050 |
Why?
|
| Actins | 1 | 2022 | 148 | 0.050 |
Why?
|
| Patient Participation | 1 | 2002 | 75 | 0.050 |
Why?
|
| Testis | 1 | 2023 | 187 | 0.050 |
Why?
|
| Viral Envelope Proteins | 1 | 2022 | 82 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2008 | 642 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 628 | 0.050 |
Why?
|
| Models, Biological | 1 | 2005 | 677 | 0.050 |
Why?
|
| Exercise Test | 2 | 2014 | 67 | 0.050 |
Why?
|
| Virus Integration | 1 | 2002 | 58 | 0.050 |
Why?
|
| Child | 3 | 2019 | 3131 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2002 | 291 | 0.050 |
Why?
|
| Patient Compliance | 2 | 2017 | 212 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 767 | 0.050 |
Why?
|
| Sequence Analysis | 1 | 2021 | 26 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 219 | 0.050 |
Why?
|
| Maryland | 1 | 2021 | 53 | 0.050 |
Why?
|
| Mice, Transgenic | 1 | 2023 | 617 | 0.050 |
Why?
|
| Fusobacteria | 1 | 2020 | 4 | 0.050 |
Why?
|
| Autoantigens | 1 | 2021 | 81 | 0.050 |
Why?
|
| Antirheumatic Agents | 1 | 2020 | 31 | 0.050 |
Why?
|
| Verbal Learning | 2 | 2012 | 15 | 0.050 |
Why?
|
| Fasting | 1 | 2020 | 54 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 143 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2018 | 1518 | 0.050 |
Why?
|
| Vaccination | 1 | 2022 | 288 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 262 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2009 | 1908 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2019 | 17 | 0.040 |
Why?
|
| Electron Transport Complex IV | 1 | 2019 | 37 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 237 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2020 | 171 | 0.040 |
Why?
|
| Animals | 4 | 2023 | 15081 | 0.040 |
Why?
|
| Cell Movement | 2 | 2013 | 571 | 0.040 |
Why?
|
| Organ Size | 1 | 2019 | 157 | 0.040 |
Why?
|
| Algorithms | 1 | 2022 | 465 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2012 | 550 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2019 | 87 | 0.040 |
Why?
|
| CpG Islands | 1 | 2019 | 97 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2021 | 268 | 0.040 |
Why?
|
| Sulfoxides | 1 | 2018 | 16 | 0.040 |
Why?
|
| Acute Disease | 1 | 2019 | 147 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2002 | 1067 | 0.040 |
Why?
|
| Rest | 1 | 2018 | 26 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 120 | 0.040 |
Why?
|
| Obesity | 1 | 2006 | 1067 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 112 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2009 | 515 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 47 | 0.040 |
Why?
|
| Aorta | 1 | 2018 | 167 | 0.040 |
Why?
|
| Philippines | 1 | 2017 | 73 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2017 | 98 | 0.040 |
Why?
|
| Creatinine | 1 | 2017 | 103 | 0.040 |
Why?
|
| Mice | 2 | 2023 | 5913 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2017 | 224 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2019 | 894 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2016 | 112 | 0.030 |
Why?
|
| Cell Separation | 1 | 2016 | 93 | 0.030 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2016 | 57 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2016 | 128 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 859 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2016 | 578 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2013 | 43 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 267 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2014 | 180 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2013 | 208 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2013 | 105 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 626 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 2012 | 107 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2012 | 107 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 562 | 0.030 |
Why?
|
| Human Immunodeficiency Virus Proteins | 1 | 2012 | 4 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2012 | 10 | 0.030 |
Why?
|
| DNA Viruses | 1 | 2012 | 14 | 0.030 |
Why?
|
| Neutralization Tests | 1 | 2012 | 53 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2014 | 753 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 583 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 441 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 4 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 7 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2010 | 5 | 0.020 |
Why?
|
| Asia, Southeastern | 1 | 2010 | 8 | 0.020 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 7 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1015 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 2010 | 18 | 0.020 |
Why?
|
| Fluconazole | 1 | 2010 | 41 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 935 | 0.020 |
Why?
|
| Biopsy | 1 | 2011 | 164 | 0.020 |
Why?
|
| Developing Countries | 1 | 2010 | 99 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 217 | 0.020 |
Why?
|
| Complement Activation | 1 | 2009 | 13 | 0.020 |
Why?
|
| Amino Acids | 1 | 2010 | 145 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2010 | 132 | 0.020 |
Why?
|
| Papillomaviridae | 1 | 2011 | 127 | 0.020 |
Why?
|
| Calorimetry, Indirect | 1 | 2009 | 9 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 321 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 389 | 0.020 |
Why?
|
| Spirometry | 1 | 2009 | 33 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2009 | 72 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 333 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 78 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 76 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2009 | 102 | 0.020 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2008 | 1 | 0.020 |
Why?
|
| Pyridines | 1 | 2009 | 116 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2009 | 208 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2009 | 253 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2009 | 174 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2008 | 103 | 0.020 |
Why?
|
| Karnofsky Performance Status | 1 | 2007 | 3 | 0.020 |
Why?
|
| Morbidity | 1 | 2007 | 91 | 0.020 |
Why?
|
| Placebos | 1 | 2006 | 37 | 0.020 |
Why?
|
| Liver | 1 | 2010 | 479 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 808 | 0.020 |
Why?
|
| Mass Screening | 1 | 2011 | 462 | 0.020 |
Why?
|
| Diet | 1 | 2012 | 801 | 0.020 |
Why?
|
| Tilt-Table Test | 1 | 2006 | 4 | 0.020 |
Why?
|
| Sample Size | 1 | 2006 | 25 | 0.020 |
Why?
|
| Respiration | 1 | 2006 | 58 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2008 | 276 | 0.020 |
Why?
|
| Cell Line | 1 | 2009 | 1354 | 0.020 |
Why?
|
| Carnitine | 1 | 2004 | 8 | 0.020 |
Why?
|
| Insulin | 1 | 2006 | 236 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2004 | 127 | 0.010 |
Why?
|
| Hip | 1 | 2003 | 3 | 0.010 |
Why?
|
| Osteonecrosis | 1 | 2003 | 5 | 0.010 |
Why?
|
| Radiography | 1 | 2003 | 72 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 2008 | 609 | 0.010 |
Why?
|
| Neuroglia | 1 | 2004 | 124 | 0.010 |
Why?
|
| Anxiety | 1 | 2010 | 754 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 1207 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2002 | 474 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 1568 | 0.010 |
Why?
|
| Apoptosis | 1 | 2003 | 1398 | 0.010 |
Why?
|